Cancer drug delivery in the nano era: An overview and perspectives (Review)

ZHEN LI1,2, SHIRUI TAN3, SHUAN LI1, QIANG SHEN4 and KUNHUA WANG1,2

1Department of Gastrointestinal and Hernia Surgery, Institute of Gastroenterology, The First Affiliated Hospital of Kunming Medical University; 2Kunming Digestive Disease Treatment Engineering Technology Center; 3College of Agricultural Sciences, Yunnan University, Kunming, Yunnan, P.R. China; 4Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Received December 2, 2016; Accepted May 29, 2017

DOI: 10.3892/or.2017.5718

Abstract. Nanomaterials are increasingly used as drug carriers for cancer therapy. Nanomaterials also appeal to researchers in the areas of cancer diagnosis and biomarker discovery. Several antitumor nanodrugs are currently being tested in preclinical and clinical trials and show promise in therapeutic and other settings. We review the development of nanomaterial drug carriers, including liposomes, polymer nanoparticles, dendritic polymers, and nanomicelles, for the diagnosis and treatment of various cancers. The prospects of nanomaterials as drug carriers for future clinical applications are also discussed.

Contents
1. Introduction
2. Liposomes
3. Polymers
4. Dendrimers
5. Micellar nanoparticles
6. Inorganic nanomaterials
7. Challenges for extending patient survival by using nanocarriers
8. Conclusion and prospects

1. Introduction

According to the World Health Organization’s World Cancer Report 2014, cancer caused 8.2 million deaths worldwide in 2012, and this number is expected to rise to 22 million by 2035 (1). Along with surgery and radiotherapy, chemotherapy is a mainstay of cancer treatment. Chemotherapy is the most frequently used systemic treatment for suppressing cancer cell proliferation, disease progression and metastasis. However, chemotherapeutic drugs not only kill proliferating cancer cells but also inevitably attack normal cells, causing adverse effects. Therefore, antitumor drug vehicles that maintain or improve the efficacy of chemotherapy while reducing the severity of reactions and side effects are urgently needed.

Nanoparticles, which can be adapted to have various biological properties and can be used in a range of settings, provide a safer and effective means of delivering chemotherapy (2-4). In the past decade, approximately 12,000 reports on the topic of nanomaterials as drug carriers in cancer treatment have been published. However, there remains a gap between technological advances and clinical applications. Many nanodrugs have been developed over the last 50 years (Fig. 1). In 1965, a group led by Bangham discovered liposomes (5). A liposomal formulation of doxorubicin (Doxil), was approved by the US Food and Drug Administration (FDA) in 1995 for treating AIDS-related Kaposi sarcoma (6). In 2005, an albumin-based nanoparticle, protein-bound paclitaxel (Abraxane) (7), has been approved by the FDA for clinical use in the treatment of breast cancer, non-small cell lung cancer, and pancreatic cancer. More recently, in 2013, targeted ado-trastuzumab emtansine (DM1) (Kadcyla) was approved for use in patients with human epidermal growth factor receptor 2-positive breast cancer (8).

Nanomaterials have a number of advantages as drug carriers. Nanocarriers can: i) increase water solubility and protect drugs dissolved in the bloodstream, improving the pharmacokinetic and pharmacological properties of the drugs; ii) target the delivery of drugs in a tissue- or cell-specific manner, thereby limiting drug accumulation in the kidneys, liver, spleen, and other non-targeted organs and enhancing therapeutic efficacy; and iii) deliver a combination of imaging
and therapeutic agents for real-time monitoring of therapeutic efficacy (9,10).

This review summarizes recent developments in the use of nanomaterials in cancer therapy. Specifically, we discuss the use of liposomes, polymer nanoparticles, dendritic polymers, and micelles as drug carriers (Fig. 2). Each category of nanomaterials has unique strengths and limitations; thus, a major goal of this review is to unveil the emerging possibilities of different nanovectors for different therapeutic applications, their relevant molecular targets, and their advantages and disadvantages.

2. Liposomes

Liposomes consist of an aqueous core surrounded by one or several layers of phospholipids and cholesterol that form a lipid bilayer. Because of this unique structure, liposomes can load and hold hydrophilic agents in the aqueous compartment and hydrophobic agents in the lipid space (11). Because their composition is similar to that of the cell membrane, liposomes are more biocompatible than other synthetic materials. In addition, distinct surface modification with functional ligands and differences in size and charge make liposomes coat with polyethylene glycol (PEG) useful for specific drug delivery tasks.

Liposomes have several additional advantages as nanocarriers for drug delivery applications. Liposomes protect the loaded drug from degradation and prevent undesirable exposure of the drug to the environment, which may slow the rate of drug release (12-14). Specific lipid species, such as cholesterol and rigid saturated lipids, stabilize the lipid bilayer to resist attack from plasma proteins and reduce drug leakage (13,14). However, the present challenge facing the development of liposomes as drug carriers is how to control their distribution and removal in vivo.

Recently, a number of studies have focused on modifying liposome drug-releasing mechanisms. For example, drug release from liposomes can be triggered by ultrasound (15,16), enzymes (17,18), light (19,20), magnetism (21-23), or hyperthermia (24). Drug-releasing liposomes may also be combined with ligand-mediated targeted delivery of nucleic acids (25-28).

Further, multifunctional and multicomponent formulations (29) have been designed to enhance localization selectivity, allowing specific targeting of distinct tissue types. Chen et al (30) used a glycyrrhetinic acid (GA)-modified liposome to load oxaliplatin (OX) for liver-targeted biodistribution studies and demonstrated that the ratio of the area under the curve (AUC) of GA-OX-liposomes to the AUC of OX-liposomes was 3.84. These results suggest that liposomes exhibit excellent tissue- and organ-specific targeting.

Liposomes not only increase the intracellular uptake of drugs but also can be used to modify anticancer agents, antibiotics, and DNA. Using an AAN-TAT-liposome platform, Liu et al (31) created a doxorubicin carrier that enhanced the drug tumoricidal effect and reduced systemic adverse effects. The RNA liposome platform is another promising strategy for boosting therapeutic efficacy (32). Recently, protocols have been designed to incorporate various types of modification to achieve a comprehensive nanodrug delivery system (Fig. 3). Chemotherapy agents, short interfering RNA, and nanoparticles, for instance, can be coupled with or encapsulated in a nanoporous silica core for simulating chemotherapy treatment with site-specific drug delivery. The supporting lipid bilayer can also be decorated with surface-targeting molecules, such as fusogenic peptide and polyethylene glycol, according to tumor type or vasculature.

Liposomes can also be used as a nonviral vector for gene delivery, making the liposome/DNA complex one of the most promising tools for cancer gene therapy (33). For example, Felgner and colleagues (34) developed cationic liposome-mediated gene delivery, in which a liposome was incorporated with an antisense oligodeoxynucleotide specific for growth factor receptor-bound protein 2 (Grb2) mRNA (L-Grb2). These liposomes inhibited Grb2 protein expression, reduced proliferation of bcr-abl-positive leukemia cells, and extended survival durations in mice bearing bcr-abl-positive leukemia xenografts (35) (Table I).

3. Polymers

Polymers can be categorized as: i) natural polymers, such as proteins, peptides, glycanse, starches, and cellulose; ii) synthetic polymers, which are synthesized from natural monomers, for instance, polyactic acid (PLA) and poly (lactic-co-glycolic acid) (PLGA); and iii) microbial fermentation polymers, such as polyhydroxybutyrate (36). Natural and synthetic polymers constitute a diversified platform for synthesis of a variety of nanoparticles, including liposomes, dendrimers, and micelles (Fig. 2).

Polymer nanoparticles, micelles, nanogels (37,38), nanospheres (39), and nanofibers for wound healing have been widely investigated (40,41). Natural polymers that are extensively used in nanoparticle synthesis include chitosan, dextran, albumin, heparin, gelatin, and collagen (42,43). Chitosan-coated PLGA nanoparticles (44,45) and chitosan nanoparticles (46-49) can carry and deliver proteins in an active form and transport them to specific organs. Synthetic polymers, such as PEGylated PLA nanoparticles and PLA-PEG-PLA nanoparticles (50-54), poly-PLGA nanoparticles (55), monomethoxypolyethylene glycol-block-polyacrylactone nanoparticles (56), and N-(2-hydroxypropyl)-methacrylamide copolymers (57), assist in the transport of proteins within the drug capsules. Furthermore, a PEG coating improves the stability of PLA nanoparticles exposed to gastrointestinal fluids and prolonged circulating time (58). Thermosensitive polymers, for which temperature is the triggering signal, can also be used to control and target drug delivery (59).

Nanosponges, which are made from biocompatible, biodegradable polymer nanoparticles, are prepared by fusing erythrocyte membrane vesicles onto PLGA nanoparticles by means of extrusion. Nanosponges are composed of hyper-cross-linked cyclodextrins connected in a three-dimensional network. Nanosponges form porous nanoparticles with sizes <500 nm, so they easily circulate in the bloodstream. As ‘sponges’, they can absorb toxins, secretions, and fragments produced by tumor cells themselves (37,38,60). Their spherical shape and negative surface charge give them a good capacity for incorporating small molecules, macromolecules, ions, and gases within their structure. Therefore, nanosponges have been designed to improve chemotherapeutic efficacy by targeting drug-resistant cells (60-62). The erythrocyte membrane can
be used as a cloak containing >3,000 nanosponges. Once they are fully loaded with toxins, nanosponges are safely disposed of by the liver with low toxicity. Therefore, nanosponges are designed to work with any type of cancer or poisoning that exhibits dysregulation of, or abnormalities in, cellular membranes.

Among the polymer-based delivery systems, only one albumin-based nanoparticle, protein-bound paclitaxel (Abraxane) (63), has been approved by the FDA for clinical use in the treatment of breast cancer, non-small cell lung cancer, and pancreatic cancer (Table II). Albumin nanoparticle that incorporates paclitaxel has improved the water solubility of...
the drug and reduced its dose-limiting toxicity by modifying its pharmacokinetic formulation (64). Given these successes, various albumin-based nanoparticles, such as ABI-008 (65), ABI-009 (66), and ABI-011 (67), are currently undergoing clinical trials. BIND-014 (68) is the first PEG-PLGA targeted polymeric nanoparticle to reach phase I/II studies for the treatment of metastatic cancer and KRAS-positive or squamous cell non-small cell lung cancer. Its pharmaceutical activity is 10-fold higher than that of conventional docetaxel in tumor sites, and it prolongs the time the drug is maintained in the circulation. Also, a targeted cyclodextrin-polymer hybrid nanoparticle (CALAA-01), a short interfering RNA inhibitor designed to inhibit tumor growth and/or reduce tumor size (69), was tested in phase I clinical trial. Current research on polymer nanocarriers focuses on elucidating their mechanisms of action, environmental responses, active targeting, and composite materials. Relevant diagnostic and therapeutic platforms still need to be constructed and evaluated.

4. Dendrimers

Dendrimers are a unique class of polymeric macromolecules found in nature. Dendrimers began to be synthesized during the period 1970-1990 by Buhleier et al (70) and Tomalia et al (71). They are globular, nanosized (1-100 nm) molecules with complex spherical structures. Dendrimers are characterized by: i) a central core; ii) branches, called ‘generations’, emanating from the core; iii) repeat units with at least one branch junction; and iv) many terminal functional groups (Fig. 4) (72,73). Unlike linear polymers, dendrimers
have a precisely controllable architecture with tailor-made surface groups. The branches of dendrimers can be decorated with a wide variety of molecules that can be utilized for passive entrapment and eventual release of drugs or other cargoes. The molecular structure of dendrimers can be fine-tuned, and because they are geometrically symmetrical and have many

| Product     | Drug               | Status  | Applications                                                                 | Refs.       |
|-------------|--------------------|---------|------------------------------------------------------------------------------|-------------|
| Doxil       | Doxorubicin        | Approved| Kaposi sarcoma, ovarian and breast cancers                                    | (6,161)     |
| DaunoXome   | Daunorubicin       | Approved| Kaposi sarcoma                                                                | (162)       |
| LipoDox     | Doxorubicin        | Approved| Ovarian and breast cancers                                                    | (163)       |
| Myocet      | Doxorubicin        | Approved| Combination therapy for metastatic breast cancer                              | (155)       |
| Marqibo     | Vincristine        | Approved| Metastatic malignant uveal melanoma                                            | (156)       |
| Onivyde     | Irinotecan         | Approved| Advanced pancreatic cancer                                                     | (164)       |
| Lipoplatin  | Cisplatin          | Phase III| Pancreatic, head and neck, breast, gastric, and non-squamous non-small cell lung cancers, mesothelioma | (165)       |
| Stimuvax    | BLP25 Tecemotide   | Phase III| Vaccine for multiple myeloma-developed encephalitis                            | (166)       |
| ThermoDox   | Doxorubicin        | Phase III| Non-resectable hepatocellular carcinoma                                         | (167)       |
| CPX-351     | Cytarabine + daunorubicin | Phase III| Acute myeloid leukemia                                                         | (168)       |
| Aroplatin   | Cisplatin analog   | Phase II| Metastatic colorectal carcinoma                                                | (169)       |
| Atragen     | Tretinoin          | Phase II| Acute promyelocytic leukemia, hormone-refractory prostate cancer               | (170)       |
| Atu027      | PKN3 siRNA         | Phase II| Solid tumors                                                                  | (171)       |
| EndoTAG-1   | Paclitaxel         | Phase II| Breast and pancreatic cancers                                                 | (172)       |
| LEP-ETU     | Paclitaxel         | Phase II| Ovarian, breast, and lung cancers                                              | (173)       |
| LE-SN38     | SN38               | Phase II| Metastatic colorectal cancer                                                   | (174)       |
| MBP-426     | Oxaliplatin        | Phase II| Gastric, gastroesophageal, and esophageal adenocarcinomas                      | (175)       |
| OSI-211     | Lurtotecan         | Phase II| Ovarian and head and neck cancers                                              | (176)       |
| SPI-077     | Cisplatin          | Phase II| Ovarian and head and neck cancers                                              | (177)       |
| Liposomal annamycin | Annamycin       | Phase I/II| Acute lymphocytic leukemia                                                     | (178)       |
| S-CKD-602   | Camptothecin analog| Phase I/II| Recurrent or progressive carcinoma of the uterine cervix                     | (179)       |
| OSI-7904L   | Thymidylate synthase inhibitor | Phase I/II| Advanced colorectal, head and neck, gastric, and gastroesophageal cancers    | (180)       |
| Anti-EGFR immuno-liposomes | Doxorubicin       | Phase I| Solid tumors                                                                  | (159)       |
| INX-0076    | Topotecan          | Phase I| Advanced solid tumors                                                         | (181)       |
| INX-0125    | Vinorelbine        | Phase I| Advanced solid tumors                                                         | (182)       |
| LEM-ETU     | Mitoxantrone       | Phase I| Leukemia, breast, stomach, liver, and ovarian cancers                         | (183)       |
| Liposomal Grb-2 | Grb2-antisense oligodeoxynucleotide | Phase I| Acute myeloid leukemia, chronic myelogenous leukemia, and acute lymphoblastic leukemia | (184)       |
| Lipoxal     | Oxaliplatin        | Phase I| Advanced gastrointestinal cancer                                               | (185)       |
| LiPlaCis    | Cisplatin          | Phase I| Advanced or refractory tumors                                                 | (186)       |

EGFR, epidermal growth factor receptor.
peripheral functional groups, an internal molecular cavity, controlled molecular weight, and nanometer size, they are excellent nanocarriers with good fluid mechanic performance, versatility, and strong adsorption ability.

Dendrimers are self-assembled and stabilize by forming organic or inorganic hybrid nanoparticles. Dendrimers can be linked to liposomes (74-76), nanoparticles (77,78), and carbon nanotubes (79-81) to modulate their solubility for use as drug carriers (74,82) and target-specific carriers (82-84) of detecting agents (such as dye molecules), affinity ligands, radioligands, imaging agents, or pharmaceutically active anti-cancer compounds.

Thanks to recent advances in synthetic chemistry and characterization techniques, novel dendritic carriers are rapidly being developed. Dendrimers are being widely investigated as gene delivery vectors. For example, polyamidoamine (PAMAM) dendrimers have the ability to condense DNA for transfection. Liu et al. (85) used five fluorinated polypropylenimine (PPI) dendrimers to improve DNA transfection efficacy. The heptafluorobutryric acid modified on the PPI dendrimer improved the efficacy of enhanced green fluorescent protein transfection in all five fluorinated PPI dendrimers by 89% over that of regular PPIs. The uptake efficacy achieved with PPI dendrimers (as indicated by both the percentage of positively stained cells and the mean fluorescence intensity) was superior to that of G5-Arg110, bPEI 25K, and four commercial transfection reagents, including Lipofectamine 2000 (with as high as 71% improvement).

Highly branched dendrimer-amplified aptamer probes can be easily rebuilt and have high affinity and specificity for a wide range of targets. They are able to reach various targets with such high sensitivity, reliability, and selectivity because of their novel optical, magnetic, electric, chemical, and biological properties (86). For instance, surface-functionalized PAMAM dendrimers with carboxyl groups, whose particles are spherical colloidal crystal clusters decorated with dendrimer-amplified aptamer probes, are designed to immobilize DNA aptamers; thus, they can serve as high-efficiency probes that target cancer cells. Malik et al. (87) showed that conjugates of cisplatin with the negatively charged 4th-generation PEGylated PAMAM dendrimer exhibited antitumor activity against B16F10 solid melanoma tumors. Methotrexate conjugated to PEGylated poly-L-lysine (PLL) dendrimers (G5, PEG1100) has been shown to accumulate in HT1080 fibrosarcoma tumors in rats and mice (88). Al-Jamal et al. (89) reported that the complexation of doxorubicin with the novel 6th-generation cationic PLL dendrimer Gly-Lys63 (NH2)64 (molecular weight 8149 kDa) produced systemic anti-angiogenic activity in tumor-bearing mice. Dendrimer nanotechnology has also been used to produce contrast

| Product | Drug       | Platform                     | Status   | Applications                                      | Refs. |
|---------|------------|------------------------------|----------|---------------------------------------------------|-------|
| Abraxane| Paclitaxel | Albumin nanoparticle         | Approved | Breast cancer, non-small cell lung cancer, pancreatic cancer (63) |
| BA-003  | Doxorubicin| Polymeric nanoparticle       | Phase III| Hepatocellular carcinoma                           | (187) |
| DHAD-PBCA-NPs | Mitoxantrone | Polymeric nanoparticle | Phase II | Hepatocellular carcinoma                           | (188) |
| ProLindac | DACHP | HPMA-polymeric nanoparticle | Phase II/III | Advanced ovarian cancer                             | (189) |
| ABI-008 | Docetaxel  | Albumin nanoparticle         | Phase I/II| Metastatic breast cancer, prostate cancer          | (65)  |
| ABI-009 | Rapamycin  | Albumin nanoparticle         | Phase I/II| Solid tumors                                       | (66)  |
| ABI-011 | Thiocolchicine dimer | Albumin nanoparticle | Phase I/II| Solid tumors, lymphoma                              | (190) |
| BIND-014 | Docetaxel | PEG-PLGA polymeric nanoparticle | Phase I/II | Non-small cell lung cancer                         | (68)  |
| Cycloset | Camptothecin | Cyclodextrin nanoparticle | Phase I/II| Solid tumors, rectal cancer, renal cell carcinoma, non-small cell lung cancer | (191) |
| CALAA-01 | siRNA targeting | Cyclodextrin nanoparticle | Phase I | Solid tumors                                       | (69)  |
| Docetaxel-PNP | Docetaxel | Polymeric nanoparticle | Phase I | Solid tumors                                       | (192) |
| Nanotax | Paclitaxel | Polymeric nanoparticle       | Phase I | Peritoneal neoplasms                               | (193) |

Table II. Drug-loaded polymer nanoparticles in clinical trials or clinical use.

| Product | Drug       | Platform                     | Status   | Applications                                      | Refs. |
|---------|------------|------------------------------|----------|---------------------------------------------------|-------|
| Abraxane| Paclitaxel | Albumin nanoparticle         | Approved | Breast cancer, non-small cell lung cancer, pancreatic cancer (63) |
| BA-003  | Doxorubicin| Polymeric nanoparticle       | Phase III| Hepatocellular carcinoma                           | (187) |
| DHAD-PBCA-NPs | Mitoxantrone | Polymeric nanoparticle | Phase II | Hepatocellular carcinoma                           | (188) |
| ProLindac | DACHP | HPMA-polymeric nanoparticle | Phase II/III | Advanced ovarian cancer                             | (189) |
| ABI-008 | Docetaxel  | Albumin nanoparticle         | Phase I/II| Metastatic breast cancer, prostate cancer          | (65)  |
| ABI-009 | Rapamycin  | Albumin nanoparticle         | Phase I/II| Solid tumors                                       | (66)  |
| ABI-011 | Thiocolchicine dimer | Albumin nanoparticle | Phase I/II| Solid tumors, lymphoma                              | (190) |
| BIND-014 | Docetaxel | PEG-PLGA polymeric nanoparticle | Phase I/II | Non-small cell lung cancer                         | (68)  |
| Cycloset | Camptothecin | Cyclodextrin nanoparticle | Phase I/II| Solid tumors, rectal cancer, renal cell carcinoma, non-small cell lung cancer | (191) |
| CALAA-01 | siRNA targeting | Cyclodextrin nanoparticle | Phase I | Solid tumors                                       | (69)  |
| Docetaxel-PNP | Docetaxel | Polymeric nanoparticle | Phase I | Solid tumors                                       | (192) |
| Nanotax | Paclitaxel | Polymeric nanoparticle       | Phase I | Peritoneal neoplasms                               | (193) |

DHAD-PBCA-NPs, mitoxantrone-loaded polybutylcyanoacrylate nanoparticles; DACHP, dicholoro (1,2-diaminocyclohexane) platinum (II); HPMA, N-(2-hydroxypropyl) methacrylamide.
agents, including agents used in molecular imaging (90). Qiao and Shi (86), and Yang et al (91), for instance, successfully synthesized ultrasmall iron oxide nanoparticles by conjugating them with Arg-Gly-Asp-modified dendrimers (G5.NHAc-RGD-Fe3O4 NPs) for targeted magnetic resonance imaging of C6 glioma cells.

Dendrimers have the advantages of being biocompatible and easily eliminated from the body. PAMAM dendrimer nanoparticles, with their large number of surface amino groups, are more biocompatible and circulate for longer in the serum than do small-molecule drugs. Dendrimer nanoparticles are eventually eliminated from the human body through the kidneys along the same metabolic pathways taken by folate (84,92), growth factors (93), peptides (94,95), and antibodies (96). However, dendrimers also have the drawbacks of being cytotoxic to normal cells, and that the end groups present on their peripheries (97) such as PAMAM, PPI, and PLL are cationic groups with physiological stability. This stability increases their cytotoxicity that can inevitably attack normal cells.

5. Micellar nanoparticles

Micellar nanoparticles possess a core and a shell structure. PEG is often used as a hydrophilic shell; shells with hydrophobic domains include PLA (52), PLGA (44,45), polystyrene, poly (cyanoacrylate), poly (vinylpyrrolidone), and polycaprolactone (56). These copolymers are widely used owing to their natural biodegradability and biocompatibility as well as their ability to entrap hydrophobic drugs. A primary mPEG-PLA polymeric micelle loaded with paclitaxel (Genexol-PM) was approved by the FDA in 2007 (98,99). It is loaded with a free-Taxol formulation and has been shown to reduce the severity of toxic effects such as hypersensitivity reactions, hyperlipidemia, and peripheral neuropathy.

Micellar nanoparticles are obtained from self-assembly of amphiphilic block copolymers in aqueous media above the critical micelle concentration (100). The core, consisting of the hydrophobic domain, acts as a reservoir that protects the drug from being dissolved, whereas the hydrophilic shell mainly confers aqueous solubility and steric stability to the micellar structure (27). With this technique, undissolvable drugs, such as paclitaxel and docetaxel, can be covered with a water-solute layer to enhance their hydrophilicity and ultimately facilitate their bioavailability. The hydrophilic shell affords protection and lengthens circulation in vivo, providing enhanced permeability and retention. In recent years, a number of nanomicellar drugs have advanced to clinical trials or to the market (Table III).

With the rise of precision medicine, micellar nanoparticles have become increasingly important for passive targeted cancer therapy. Peptide modification on the surface...
of the micelle can be used effectively for precise targeting. Integrin-binding sequence peptides with covalent bonds to the micelle can actively target tumors (101). Block copolymers are environmental response modifiers that display a physico-chemical response to stimuli such as temperature (102-104), pH (105), light (106), or electricity (107). Some block copolymers can produce functional signals and higher levels of signaling (103,108); thus, micelles made from them are called ‘intelligent’ block copolymer micelles. The self-assembly of such polypeptide-based copolymers can be triggered by temperature and pH changes (105). Poly (N-isopropylacrylamide) (PNIPAM) is a temperature-sensitive polymer segment with a lowest critical solution temperature of 31-32°C (105). It quickly switches from a hydrated to a dehydrated state, using PNIPAM-OH and the ring-opening polymerization reaction synthesis of PLA (PNIPAM-b-PLA) (104) and self-assembles into dual-response micelle carriers. A series of dual-stimuli responsive polymers such as PNIPAM-b-PGA and PNIPAM-b-PLL have been synthesized as copolymer micelle materials (108). Doxorubicin can be effectively encapsulated in PNIPAM-block-poly (L-histidine) (PNIPAM-b-PLH) micelle carriers as a controlled delivery system for the treatment of hepatocellular carcinoma (109). Light-sensitive groups, including the azide, cinnamon acyl, screw pyran, coumarin, and 2-nitrobenzyl groups, have also been widely used in cancer therapeutic settings (106,110,111). Photodynamic therapy (PDT) is a non-invasive treatment modality for a variety of diseases including cancer (112). PDT based upon upconversion nanoparticles (UCNPs) has received much attention in recent years. Under near-infrared (NIR) light excitation, UCNPs are able to emit high-energy visible light, which can activate surrounding photosensitiser (PS) molecules to produce singlet oxygen and kill cancer cells (113,114) also represent a promising direction in future research (115,116).

The greatest benefit of biodegradable drug delivery systems is the controlled release of the drug payload to a specific site and the degradation into nontoxic materials for elimination from the body via metabolic pathways (117). Organelle-targeted biodegradable copolymers, mitochondria-targeting gold-peptide, and radiation-hyperthermia nanoassembly-copolymers (118,119) are used to evaluate micro-environmental change by taking advantage of the sensitivity of mitochondria to temperature elevation. In the presence of a thermal stimulus, the passive targeted biodegradable micellar nanoparticles of a copolymer-controlled drug release system are activated, resulting in slow degradation of the nanoparticles into smaller fragments and the release of carried products, which eventually enhance the drug’s cytotoxic effects on cancer cells. Currently, new biocompatible and/or biodegradable stimuli-responsive copolymers that form stable micellar systems capable of encapsulating a broad range of chemotherapeutic agents are being developed (120,121).

It is generally accepted that nonviral vectors are safer than viral vectors for gene transfer (122). Biodegradable copolymers based on polylignane are the first nanoparticles used for gene transfer. Currently, PEG-grafted PLGA-PLL (123), pluronlc polyethylenimine (PEI), polyethylenimine acid (124), and phosphate (125) micelles are being used as gene carriers for biological separation and cancer diagnosis. However, applications of cationic polymer-based gene delivery systems are limited because the polymers interact with the cell membrane and produce increased toxicity (122).

6. Inorganic nanomaterials

Various forms of inorganic nanoparticles, including quantum dots, superparamagnetic iron oxides, gold nanoparticles, carbon nanotubes, and other metallic and non-metallic nanoparticles or nanoclusters, enhance the efficiency of radiotherapy and improve tumor imaging (119,126). Several of these inorganic nanoparticles are sufficiently small (10-100 nm) to penetrate the capillaries and can be taken up in distinct tissues. Others are larger and need to be delivered at disease-specific anatomic sites for passive targeting. Multifunctional nanodevices are also emerging as tools to target cancer (42,43,127). Such devices can contain not only the drug payload but also specific receptor-targeting agents, such as antibodies or ligands, as well as magnetic resonance imaging contrast agents. Quantum dots and gold nanoparticles exhibit unique optical, electrical, and magnetic properties (128) that are beneficial for imaging the intracellular localization and trafficking of multifunctional carriers. Drugs can also be delivered at specific sites after they are attached, encapsulated, absorbed, entrapped, or dissolved in the nanomaterial matrix. However, in early-stage clinical trials, some inorganic nanomaterials, such as gold nanoparticles (129) and silica nanoparticles (130), have encountered obstacles, including toxicity and a lack of stability. Of the iron oxide nanoparticles, NanoTherm (131), used for the treatment of glioblastoma, is the only one that has obtained approval for clinical use. With NanoTherm, tumors can be thermally ablated by magnetic hyperthermia induced by entrapped superparamagnetic iron oxides.

7. Challenges for extending patient survival by using nanocarriers

Many solid tumors develop several biological features distinguished from those of normal tissues (132). Abnormal tumor structures including physically compromised vasculature, abnormal extracellular matrix (ECM), and high interstitial fluid pressure (IFP), can create constraints that compromise effective delivery of nanotherapeutics (133,134). There are also extravascular barriers to overcome, whereby nanoparticles can extravasate but cannot penetrate through the ECM of the tumors (135). It is well recognized that the irregularity of the tumor vasculature with its abnormal blood flow and impaired venous and lymphatic drainage creates high interstitial fluid pressure, making the diffusion of nutrients and chemotherapeutics throughout the tumor very inefficient, thus presenting challenges to effective diffusion of nanocarriers as well (136).

Liposomes and polymers are the most widely used biodegradable nanocarriers because of their biocompatibility, biodegradability, and mechanical properties. However, because of adverse effects and the still-unclear mechanisms of interaction among nanoparticles, the tumor microenvironment, and tumor cells, these nanocarriers may offer only brief extension of patient survival (Table IV). Despite numerous achievements in liposomal drug delivery, current liposomal formulations have primarily reduced systemic toxicity rather...
Table IV. Nanomaterials as drug carriers: advantages and disadvantages.

| Nanomaterials       | Advantages                                                                 | Disadvantages                                                   |
|---------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------|
| Liposomes           | Controlled release, reduced toxicity, improved stability                   | Distribution and removal mechanism, breakage in vivo             |
| Polymers            | Variety, controllable molecular weight                                      | Inflammatory response, degradation pathway                       |
| Dendrimers          | Nanosized cavity, controlled release, self-assembly                        | Immunoreaction, hematological toxicity                           |
| Micellar nanoparticles | Simple prescription, passive targeting                                    | Scale-up production, cytotoxicity                               |
| Inorganic nanomaterials | Multifunctional, modifiable, ability to combine diagnosis and treatment | Metal toxicity, stability, storage                              |

than increasing efficacy. For instance, hydrophilic drugs such as cisplatin are decorated with liposomal bilayers to reduce drug internal toxicity. However, it needs time to degrade the liposome vehicle for the release of the embedded pharmaceutical. Therefore, long systemic circulation and minimal side effects could result in poor efficacy in vivo. Nevertheless, it is still challenging to achieve an optimal balance between high and specific drug bioavailability in tumor tissue and prolonged liposome stability in systemic circulation (137).

Despite many advances in the production of more stable, efficient, and safe biopolymers, there remain controversies regarding the safety of polymeric nanomaterials. Some polymers are themselves cytotoxic (41,138). It has been demonstrated, for example, that PEI destabilizes the plasma membrane and activates effector caspase-3; thus, PEI appears to be a proapoptotic agent (138). Inflammatory and immune responses have also been reported (139-141). However, PLGA can be formulated as an acidic product to provoke inflammatory responses, and it has shown minimal systemic toxicity and excellent biocompatibility in vitro and in vivo (142). Thus, advancements in formulating, synthesizing, and modifying biodegradable polymers promise to improve treatment efficacy and reduce adverse effects.

Compared to other types of nanocarriers, dendrimers provide more opportunities for design and adaptation owing to their peculiar tailor-made surfaces. Toxicity associated with dendrimers is primarily attributed to the end groups present on their peripheries (97). Cationic dendrimers with high charge density and high molecular weight, such as PAMAM, PPI, and PLL, are more stable in physiological conditions. This stability increases their cytotoxicity, owing to the excess positive charges on the periphery, which destabilize the cell membrane. However, stability may also cause several adverse effects (143-145). Fortunately, neutral or anionic groups such as sulfonated, carboxylated, and phosphonated groups have been shown to be less toxic (73). In light of this progress, the next step will be to modify the surface groups of dendrimers with minimally toxic reagents in order to adapt them to physiological conditions.

Other nanoparticles of particularly urgent concern are micelles and inorganic nanomaterials, which present challenges with instability, potential toxicity, cytotoxicity, immune response, and chronic inflammation (146,147). For specific targeted therapy, micelles and inorganic nanomaterials can be decorated with receptor-stimuli agents such as PH, light and magnetic resonance imaging contrast agents, one major limitation of this treatment methodology in clinical applications is the poor tissue penetration ability (148,149).

Research aimed at overcoming these drawbacks will facilitate the use of nanomaterials as drug delivery vehicles and eventually improve patient survival. Ideally, an anticancer nanotherapeutic should be able to reach tumors without systemic loss, easily penetrate into the core of the tumor mass, enter tumor cells where their target molecules reside, and completely eradicate the tumors.

8. Conclusion and prospects

Nanotechnology receives extraordinary attention, and its applications in cancer treatment are relatively new and ever-evolving. Nonetheless, it is clear that nanomaterials are promising tools for cancer treatment. In spite of the progress being made in developing drug delivery systems for cancer therapy, a number of critical issues still need to be addressed. Molecularly targeted drugs preferentially modulate functional proteins, so they can be used to treat diseases (150), like cancers, that are characterized by abnormal protein expression and activation. However, such targeting mechanisms can be challenged by the stability of nanomaterials, the development of multi-drug resistance, and the dysregulated accumulation of cancer cells. The ability to decorate nanomaterial shells with multiple chemically or physically active components permits the delivery of different drugs. Therefore, nanomaterial drug carriers can be organized and optimized for site-specific chemotheraphy, photodynamic therapy, and radiotherapy. Although the benefits of metal-based nanoparticles are remarkable, toxicity remains a critical issue. Nano-toxicological issues also need to be addressed so that more effective cancer therapeutic strategies can be developed. Notably, combination therapeutic regimens for different cancer types remain a challenge because of the diverse mechanisms of cancer development. Combination therapy with nanoparticle drug carriers, therefore, warrants further study at the preclinical and clinical levels. Other challenges exist for modified and functionalized nanomaterials with well-established formulations, including improving the localization, biodistribution, biocompatibility, and efficacy of nanodrug systems in vivo, to meet the requirements of precision cancer diagnosis and therapy.
Acknowledgements

We thank Ms. Yasmin Salina at the Department of Clinical Cancer Prevention, and Dr Amy Ninetto, ELS at the Department of Scientific Publications, The University of Texas MD Anderson Cancer Center for proofreading and editing of this manuscript. This study was supported by the Scholarship Award for Excellent Doctoral Student Granted of Yunnan Province (6011418150 to Z. Li), the Foundation of Leading Talent Program of Health and Family Planning Commission of Yunnan Province (no. L-201205 to K. Wang), and the Foundation of Institute of Gastroenterology, Research institutions attached to Health and Family Planning Commission of Yunnan Province (2014NS122 to K. Wang).

References

1. Shanthi M: Global Status Report on Noncommunicable Diseases 2014, WHO Press, World Health Organization, Geneva, 2014.
2. LaVan DA, McGuire T and Langer R: Small-scale systems for in vivo drug delivery, Nat Biotechnol 21: 1184-1191, 2003.
3. Shi J, Xiao Z, Kamaly N and Farokhzad OC: Self-assembled targeted nanoparticles: Evolution of technologies and bench to bedside translation, Acc Chem Res 44: 1123-1134, 2011.
4. Langer R: New methods of drug delivery, Science 249: 1527-1533, 1990.
5. Bangham AD, Standish MM and Watkins JC: Diffusion of univalent ions across the lamellae of swollen phospholipids, J Mol Biol 13: 238-252, 1965.
6. James ND, Coker RJ, Tomlinson D, Harris JR, Gompels M, Pinching AJ and Stewart JS: Liposomal doxorubicin (Doxil): An effective new treatment for Kaposi's sarcoma in AIDS, Clin Oncol (R Coll Radiol) 6: 294-296, 1994.
7. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P and Hawkins MJ: Abxarana, a novel Crenorphor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17: 1263-1268, 2006.
8. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF and Farokhzad OC: Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem Soc Rev 41: 2971-3010, 2012.
9. Burgess P, Hutt PB, Farokhzad OC, Langer R, Minick S and Zale S: On firm ground: IP protection of therapeutic nanoparticles. Nat Biotechnol 28: 1267-1270, 2010.
10. Farokhzad OC and Langer R: Impact of nanotechnology on drug delivery. Nat Rev Drug Discov 10: 342-343, 2011.
11. Chen J, Jiang H, Wu Y, Li Y and Gao Y: A novel glycurrhetic acid-modified oxaplatin liposome for liver-targeting and in vitro/vivo evaluation. Drug Des Devel Ther 9: 2265-2275, 2015.
12. Liu Z, Xiong M, Gong J, Zhang Y, Bai N, Luo Y, Li L, Wei Y, Liu Y, Tan X, et al: Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment. Nat Commun 5: 4280-4291, 2014.
13. Allen TM and Cleland LG: Serum-induced leakage of liposome contents. Biochim Biophys Acta 597: 418-426, 1980.
14. Senior J and Gregoriadis G: Is half-life of circulating liposomes determined by changes in their permeability? FEBS Lett 145: 109-114, 1982.
15. Huang-SL and MacDonald RC: Acoustically active liposomes for drug encapsulation and ultrasound-triggered release. Biochim Biophys Acta 1655: 134-141, 2004.
16. Ueno Y, Sonoda S, Suzuki R, Yokouchi M, Kawasoe Y, Tachibana K, Maruyama K, Sakamoto T and Komiya S: Combination of ultrasound and bubble liposome enhance the effect of doxorubicin and inhibit murine osteosarcoma growth. Cancer Biol Ther 12: 270-277, 2011.
17. Pak CC, Erkuluka RK, Ahl PL, Jonaff AS and Meers P: Elastase activated liposomal delivery to nucleated cells. Biochim Biophys Acta 1419: 111-126, 1999.
18. Meers P: Enzyme-activated targeting of liposomes. Adv Drug Deliv Rev 53: 265-272, 2001.
19. Gerasimov OV, Boomer JA, Qualls MM and Thompson DH: Cytosolic drug delivery using pH- and light-sensitive liposomes. Adv Drug Deliv Rev 38: 317-338, 1999.
20. Bondurant B, Mueller A and O'Brien DF: Photoinitiated destabilization of sterically stabilized liposomes. Biochim Biophys Acta 1511: 112-122, 2001.
21. Du B, Han S, Li H, Zhao F, Su X, Cao X and Zhang Z: Multi-functional liposomes showing radiofrequency-triggered release and magnetic resonance imaging for tumor multi-mechanism therapy. Nanoscale 7: 5411-5426, 2015.
22. Aric AA and Lee JK: Effect of boron doped fullerene C 60 film coating on the electrochemical characteristics of silicon thin film anodes for lithium secondary batteries. Synth Met 161: 158-165, 2011.
23. Dao TT, Matsuhashi T and Murata H: Organic nonvolatile memory transistors based on fullerene and an electron-trapping polymer. Org Electron 13: 2709-2715, 2012.
24. Paphadjopoulos D, Jacobson K, Nir A, Zeller H, Isaac T: Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochim Biophys Acta 311: 330-348, 1973.
25. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G and Sood AK: Therapeutic Epa2A gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65: 6910-6918, 2005.
26. Miller CR, Bondurant B, McLean SD, McGovern KA and O'Brien DF: Liposome-cell interactions in vitro: Effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 37: 12875-12883, 1998.
27. Wolfrum C, Shi S, Jayaprabak KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrisse K, Nduemo EM, et al: Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25: 1149-1157, 2007.
28. Wang Z, Yu Y, Dai W, Lu J, Cui J, Wu H, Yuan L, Zhang H, Wang X, Wang J, et al: The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer. Biomaterials 33: 8451-8460, 2012.
29. Hovi DJ: Drug delivery: One nanoparticle, one kill. Nat Mater 10: 342-343, 2011.
30. Chen J, Jiang H, Wu Y, Li Y and Gao Y: A novel glycurrhetic acid-modified oxaplatin liposome for liver-targeting and in vitro/vivo evaluation. Drug Des Devel Ther 9: 2265-2275, 2015.
31. Liu Z, Xiong M, Gong J, Zhang Y, Bai N, Luo Y, Li L, Wei Y, Liu Y, Tan X, et al: Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment. Nat Commun 5: 4280-4291, 2014.
32. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, et al: Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of metastatic breast cancer. J Natl Cancer Inst 103: 1934-1940, 2011.
33. Lee JH and Lee MJ: Liposome mediated cancer gene therapy: Clinical trials and their lessons to stem cell therapy. Bull Korean Chem Soc 33: 433-442, 2012.
34. Aronsson PL, Gidek TR, Ralls JP, Roman M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM and Danielsen M: Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 7413-7417, 1987.
35. Tari AM, Gutiérrez-Puente Y, Monaco G, Stephens C, Sun T, Rosenblum M, Belmont J, Arlinghaus R and Lopez-Berestein G: Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts. Int J Oncol 31: 1243-1250, 2007.
36. Yu L, Dean K and Li L: Polymer blends and composites from renewable resources. Prog Polym Sci 31: 576-602, 2006.
37. Hu C-MJ, Zhang L, Aryal S, Cheung C, Fang RH and Zhang L: Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA 108: 10980-10985, 2011.
38. Sinha M, Banik RM, Haldar C and Maiti P: Development of ciprofl oxacin hydrochloride loaded poly (ethylene glycol)/ chitosan scaffold as wound dressing. Nat Mater 20: 799-807, 2015.
39. Nguyen TTT, Ghosh C, Hwang S-G, Dai Tran L and Park JS: Characteristics of curcumin-loaded poly (lactic acid) nanofibers for wound healing. J Mater Sci Mater Med 24: 7125-7133, 2013.
Tan S, Gan C, Li R, Ye Y, Zhang S, Wu X, Yang YY, Fan W and Wu M: A novel chemosynthetic peptide with β-sheet motif efficiently kills Klebsiella pneumoniae in a mouse model. Int J Nanosci 10: 2985-2996, 2015.

Janib SM, Moses AS and MacKay JA: Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 62: 1052-1065, 2010.

Grossman JH and McNeil SE: Nanotechnology in cancer medicine. Phys Today 65: 38-42, 2012.

Mishra S, De A and Mozumdar S: Synthesis of thermoresponsive polymers for drug delivery. In: Drug Delivery System. Springer, Clifton, pp77-101, 2014.

Gundogdu N and Cetin M: Chitosan-poly (lactide-co-glycolide) (CS-PGLA) nanoparticles containing metformin HCl: Preparation and in vitro evaluation. Pak J Pharm Sci 27: 1923-1929, 2014.

Tajmir-Riahi HA, Nafshi S, Sanyakamdhorn S, Agudelo D and Chanphai P: Applications of chitosan nanoparticles in drug delivery. Methods Mol Biol 1141: 165-184, 2014.

Malhotra M, Tomaro-Duchesneau C, Saha S and Prakash S: Intranasal delivery of chitosan-siRNA nanoparticle formulation to the brain. Methods Mol Biol 1141: 233-247, 2014.

Raja MAG, Katas H and Jing Wen T: Stability, intracellular delivery. Methods Mol Biol 1141: 233-247, 2014.

Malhotra M, Tomaro-Duchesneau C, Saha S and Prakash S: Intranasal delivery of chitosan-siRNA nanoparticle formulation to the brain. In: Drug Delivery System. Jain KK (ed). Springer New York, NY, pp233-247, 2014.

Yang X, Wu S, Wang Y, Li Y, Chang D, Luo Y, Ye S and Hong Z: Evaluation of self-assembled HCPT-loaded PEG-b-PLA nanoparticles by comparing with HCPT-loaded PLA nanoparticles. Nanoscale Res Lett 9: 2408, 2014.

Sun C, Wang X, Zheng Z, Chen D, Wang X, Shi F, Yu D and Wu H: A single dose of dexamethasone encapsulated in poly-ethylene glycol-coated polystyrene nanoparticles augments cisplatin-induced hearing loss following round window membrane administration. Int J Nanomedicine 10: 3567-3579, 2015.

Rabanel J-M, Faivre J, Tehrani SF, Lalloz A, Hildgen P and Authelin J-R: Preparation and in vitro evaluation. Pak J Pharm Sci 27: 1923-1929, 2014.

Xie Y, Yi Y, Hu X, Shangguan M, Wang L, Lu Y, Qi J and Wu W: Synchronous microencapsulation of multiple components in silymarin into PLGA nanoparticles by an emulsification/solvent evaporation method. Pharm Dev Technol 21: 672-679, 2016.

Xiong W, Peng L, Chen H and Li Q: Surface modification of MPEG-b-PCL-based nanoparticles via oxidative self-polymerization of dopamine for malignant melanoma therapy. Int J Nanomedicine 10: 2985-2996, 2015.

Zhang R, Luo K, Yang J, Sima M, Sun Y, Janat-Amsbury MM and Kopecek J: Synthesis and evaluation of a buckyback biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel. J Control Release 166: 66-74, 2013.

Wang Q, Tang H and Wu P: Aqueous solutions of poly (ethylene oxide)-poly (l-lysine): Thermostressive behavior and distinct multiple assembly processes. Langmuir 31: 6497-6506, 2015.

Priya James H, John R, Alex A and Anoop KR: Smart polymers for the controlled delivery of drugs - a concise overview. Acta Pharm Sinica B 4: 104-110, 2014.

Trotta F, Dianzani C, Caldera F, Moggetti B and Cavalli R: The application of nanoposphes to cancer drug delivery. Expert Opin Drug Deliv 11: 931-941, 2014.

Hu C-MJ, Fang RH, Wang K-C, Luk BT, Thamphiwatana S, Debnath J, Angustaplikul P, Chen WH, Kroll AV, et al: Nanoparticle biosinterfacing by platelet membrane clcoaking. Nature 526: 118-121, 2015.

Hu CM, Fang RH, Luk BT and Zhang L: Nanoparticle-detained toxins for safe and effective vaccination. Nat Nanotechnol 8: 933-938, 2013.

More E, Scapelli GP, Miele E, Tomao F and Tomao S: Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomed 4: 99-105, 2009.

Hawkings MJ, Soon-Shiong P and Desai N: Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60: 105-109, 2008.

Zheng Y-R, Suntharalingam K, Johnstone TC, Yoo H, Lin W, Brooks JK and Lippard SJ: Pt (IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J Am Chem Soc 136: 8790-8794, 2014.

Cirtsea D, Hideshima T, Rodig S, Santo L, Pozzi S, Velt A, Georg T, Perezone G, Gu P, Patel S et al: Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 9: 963-975, 2010.

Fu Q, Sun J, Zhang W, Sui X, Yan Z and He Z: Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Patents Anticancer Drug Discov 4: 262-272, 2009.

Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, Burris HA III, Hart LL, Low SC, Parsons DM, et al: Phase I study of PSMA-targeted docetaxel-containing nanoparticle BL20-510 for the treatment of advanced solid tumors. Clin Cancer Res 22: 3157-3163, 2016.

Zuckerman JE, Grilli I, Tolcher A, Heidel JD, Lim D, Morgan R, Chmielowski B, Ribas A, Davis ME and Yen Y: Correlating animal and human phase Ia/ib clinical data with CALA-A1-01, a targeted, polymer-based nanoparticle system containing siRNA. Proc Natl Acad Sci USA 111: 11449-11454, 2014.

Buhleier E, Wehner V and Vögtle F: ‘Cascade’- and ‘nonskid-chain-like’ syntheses of molecular cavity topologies. Synthesis (Mass) 155-158: 1978, 1978.

Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, Roeck J, Ryder J and Smith P: A new class of polymers: Starburst-dendritic macromolecules. Polym J 17: 117-132, 1985.

Gillies ER and Fréchet JM: Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 10: 35-43, 2005.

Kesharwani P, Jain K and Jain NK: Dendrimer as nanocarrier for drug delivery. Prog Polym Sci 39: 268-307, 2014.

Khopade AJ, Caruso F, Tripathi P, Nagaich S and Jain NK: Effect of dendrimer on entrapment and release of bioactive from liposomes. Int J Pharm 232: 157-162, 2002.

Papagiannaros A, Dimas K, Papaiannou GT and Demetzos C: Doxorubicin-PAMAM dendrimer complex attached to liposomes: Cytotoxic studies against human cancer cell lines. Int J Nanomed 302: 29-38, 2014.

Purohit G, Sakthivel T and Florence AT: Interaction of cationic polypyrrole film. Anal Chim Acta 597: 145-150, 2007.

Brooks JG and Lippard SJ: Pt (IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J Am Chem Soc 136: 8790-8794, 2014.

}
84. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, Patri AK, Thomas T, Mulé J and Baker JR Jr: Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor thrombosis. J Control Release 19: 1310-1316, 2002.

85. Liu H, Wang Y, Wang M, Xiao J and Cheng Y: Fluorinated poly(propyleneimine) dendrimers as gene vectors. Biomaterials 35: 5407-5413, 2014.

86. Qiao Z and Shi X: Dendrimer-based molecular imaging contrast agents. Prog Polym Sci 44: 1-27, 2015.

87. Malik N, Eswara EG and Duncan R: Dendrimer-platinate: A novel approach to cancer chemotherapy. Anticancer Drugs 10: 767-776, 1999.

88. Kaminskas LM, Kelly BD, McLeod VM, Boyd BJ, Krippner GY, Williams ED and Porter CJ: Pharmacokinetics and tumor disposition of PEGylated, methotrexate-conjugated poly-l-lysine dendrimers. Mol Pharm 6: 1190-1204, 2009.

89. Al-Jamal KT, Al-Jamal WT, Wang JT-W, Rubino N, Buddle J, Gathercole D, Zhol M and Kostarelos K: Cationic poly-l-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo. ACS Nano 7: 1905-1917, 2013.

90. Huang Z, Sengar RS, Nigam A, Abadjian MC, Potter DM, Grothjahn DB and Wiener EC: A fluorinated dendrimer-based nanotechnology platform: New contrast agents for high field imaging. Invest Radiol 45: 641-654, 2010.

91. Yang J, Luo Y, Xu Y, Li J, Zhang Z, Wang H, Shen M, Shi X and Zhang G: Conjugation of iron oxide nanoparticles with RGD-modified dendrimers for targeted tumor MR imaging. ACS Appl Mater Interfaces 7: 5420-5428, 2015.

92. Shi X, Wang SH, Van Antwerp ME, Chen X and Baker JR Jr: Targeting and detecting cancer cells using spontaneously formed multilayered dendrimer-stabilized gold nanoparticles. Analyst (Lond) 134: 1373-1379, 2009.

93. Thomas TP, Shukla R, Kotlyar A, Liang B, Ye JY, Norris TB and Baker JR Jr: Dendrimer-epidermal growth factor conjugate displays superagonist activity. Biomacromolecules 9: 603-609, 2008.

94. Hill E, Shukla R, Park SS and Baker JR Jr: Synthetic PAMAM-RGD conjugates target and bind to odontoblast-like MDPC 23 cells and the predentin in tooth organ cultures. Bioconjug Chem 18: 1756-1762, 2007.

95. Lesnli KG, Wariari SM, Nair BM, Tam W, Hutson A, Balogh LP and Khan MK: Synthesis and characterization of PAMAM dendrimer-based multifunctional nanodevices for targeting alphavbeta3 integrins. Bioconjug Chem 18: 1148-1154, 2007.

96. Thomas PP, Patri AK, Myc A, Myaing MT, Ye JY, Norris TB and Baker JR Jr: In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. Biomacromolecules 5: 2269-2274, 2004.

97. Chen H-T, Neerman MF, Parrish AR and Simanek EE: Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on candidate vesicle vehicles for drug delivery. J Am Chem Soc 126: 10044-10048, 2004.

98. Ahn HK, Jung M, Sym JS, Shin DB, Kang SM, Kyyung SY, Park JW, Jeong SH and Cho EK: A phase II trial of Cremophor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 74: 277-282, 2010.

99. Park S and Healy KE: Nanoparticulate DNA packaging using terpolymers of poly (lysine-g-(lactide-b-ethylene glycol)). Bioconjug Chem 14: 311-319, 2003.

100. Sun T-M, Du J-Z, Yan L-F, Mao H-Q and Wang J: Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymers for siRNA delivery. Biomaterials 29: 4348-4355, 2008.

101. Gao Y, Zhou Y, Zhao L, Zhang C, Li Y, Li J, Li X and Liu Y: Enhanced antitumor efficacy by cyclic RGDyK-conjugated and paclitaxel-loaded pH-responsive polymeric micelles. Acta Biomater 23: 127-135, 2015.

102. Kohori F, Sakai K, Aoyagi T, Yokoyama M, Sakurai Y and Okano T: Preparation and characterization of thermally responsive block copolymer micelles comprising poly (N-isopropylacrylamide-b-DL-lactide). J Control Release 55: 87-98, 1998.

103. He C, Zhao C, Chen X, Guo Z, Zhang X and Jing X: Novel pH- and temperature-responsive bock copolymers with tunable pH-responsive range. Macromol Rapid Commun 29: 490-497, 2008.

104. Xu F, Yan T-T and Luo Y-L: Studies on micellization behavior of thermosensitive PNIPAAm-b-PLA amphiphilic block copolymers. J Nanosci Nanotechnol 12: 2287-2291, 2012.
150. Chen H, Yang Z, Ding C, Chu L, Zhang Y, Terry K, Liu H, Yang Y, Shao Q, Deng R, Wang C, Teng X, Cheng K, Cheng Z, Dreaden EC, Austin LA, Mackey MA and El-Sayed MA: Size
149. Jain K, Kesharwani P, Gupta U and Jain NK: Dendrimer toxicity: Madaan K, Kumar S, Poonia N, Lather v and Pandita D: Ceonzo K, Gaynor A, Shaffer L, Kojima K, v acanti CA and Nicolete R, dos Santos DF and Faccioli LH: The uptake of Kim J, Dadsetan M, Ameenuddin S, Windebank AJ, Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G Holback H and Yeo Y: Intratumoral drug delivery with nanopar- Jain RK, Martin JD and Stylianopoulos T: The role of mechan
138. Liu D, He C, Wang AZ and Lin W: Application of liposomal Let's meet the challenge. Int J Pharm 394: 122-142, 2010.
137. Liu D, He C, Wang AZ and Lin W: Application of liposomal linked paclitaxel prodrug micellar nanoparticles as a versatile Holback H and Yeo Y: Intratumoral drug delivery with nanopar-"
Awada A, Bondarenko IN, Bonneteer J, Nowara E, Ferrero JM, Bakshi AV, Wilke C and Piccart M: CT4002 study group: A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann Oncol 25: 824-831, 2014.

Slingerland M, Guchelaar H-J, Rosing H, Scheule ME, van Warmerdam LJ, Beijnen JH and Gelderbloem H: Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: A randomized, two-period crossover study in patients with advanced cancer. Clin Ther 35: 1946-1954, 2013.

Bala V, Rao S, Boyd BJ and Prestidge CA: Prodrug and nanomedicine approaches for the delivery of the campothecin analogue SN38. J Control Release 172: 48-61, 2013.

Senzer NN, Matsuno K, Yamagata N, Fujisawa T, Wasserman E, Sutherland W, Sharma S and Phan A: Abstract C36: MBP-426, a novel liposome-encapsulated oxaliplatin, in combination with 5-FU/leucovorin (LV): Phase I results of a Phase I/II study in gastro-esophageal adenocarcinoma, with pharmacokinetics. Mol Cancer Ther 8 (Suppl. 1): C36-C36, 2009. doi: 10.1158/1535-7163.TARG-09-C36.

Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, Sivret J, Rusk J and Barrett E: A phase II study of liposomal furtoscan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol 93: 229-232, 2004.

Malbouisson P, Maciel J, Heffner TL, Parekh S, Andreeff M, O'Brien S and Kantarjian HM: Administration of recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as a novel therapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma of the head and neck. Cancer Res 68: 1503-1503, 2008.

Stathopoulos GP, Boulakis T, Kouveratis A and Stathopoulos J: Liposomal oxaliplatin in the treatment of advanced cancer: A phase I study. Anticancer Res 26B: 1489-1493, 2006.

Oncology Venture: Oncology Venture presents LiPlaCis on Abstract A89: A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388 (Lipotecan®), administered intravenously to patients with advanced solid tumors. Mol Cancer Ther 10 (Supplement 1): 89, 2011.

Luo Y, Zeng H, Jia Y, Zhou H and Gao G: A randomized phase II study comparing paclitaxel-carboplatin with paclitaxel-carboplatin in patients with recurrent platinum-resistant ovarian carcinoma. J Clin Oncol 33: 3527, 2015.

Kato K, Chihara S, Yoshikawa T, Yamaguchi K, Tsuji T, Esaki T, Sakai K, Kimura M, Hamaguchi T, Shimada Y, et al: Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs 30: 1621-1627, 2012.

Endo K, Ueno T, Kondo S, Wakisaka N, Murono S, Ito M, Kataoka K, Kato Y and Yoshizaki T: Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma. Cancer Sci 104: 369-374, 2013.

Tsui A, Hamaguchi T, Yamaguchi K, et al: A phase II study of NK012, a polymeric micelle formulation of SN-38, in colorectal cancer patients who had received prior oxaliplatin-based regimen. Journal 33: 3527, 2015.

Ghamande S, Lin C-C, Cho DC, Coleman T, Chaudhary I, Shapiro GI, Silverman M, Kuo M-W, Mach WB, Tseng Y, et al: Abstract A89: A Phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388 (Lipotecan®), administered intravenously to patients with advanced solid tumors. Mol Cancer Ther 10 (Supplement 1): 89, 2011.

Yuen E, Zeng H, Zhou H, Jia Y, Zhou H, Luo Y, Zeng H, Jia Y, Zhou H, Gao G, Kato K, Chihara S, Yoshikawa T, Yamaguchi K, Tsuji T, Esaki T, Sakai K, Kimura M, Hamaguchi T, Shimada Y, et al: A randomized clinical trial of a novel DNA topoisomerase-1 inhibitor, TLC388 (Lipotecan®), administered intravenously to patients with advanced solid tumors. Int J Nanomed 9: 3005-3012, 2014.

Takahashi A, Yamamoto Y, Yasunaga M, Koga Y, Kuroda J, Takigahira M, Harada M, Saito H, Hayashi T, Kato Y, et al: NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Sci 104: 920-925, 2013.

Owen SC, Chan DP and Shoichet MS: Polymeric micelle stability. Nano Today 7: 53-65, 2012.